aid: orsobio
name: OrsoBio
image: https://orsobio.com/wp-content/uploads/2022/10/orso-bio.png
description: >-
  OrsoBio is a privately held, clinical-stage biopharmaceutical company founded in 2021 and
  headquartered in Palo Alto, California, developing first-in-class oral therapies that restore
  energy homeostasis in patients living with severe metabolic disorders — obesity, type 2 diabetes,
  severe dyslipidemias, lipodystrophies and MASH. The name is drawn from the metabolic adaptability
  of bears ("orso" in Italian). Its pipeline is led by three mitochondrial protonophores — TLC-6740,
  TLC-1180 and TLC-1235 — intended to increase energy expenditure and improve metabolic and
  cardiovascular health, alongside an LXR inverse agonist (TLC-2716) for severe hypertriglyceridemia
  and MASH, an ACC2 inhibitor (TLC-3595) for insulin sensitivity in type 2 diabetes, and an ACMSD
  inhibitor to augment NAD+ biosynthesis in metabolic and inflammatory liver and kidney disorders.
  The company closed an oversubscribed $67 million Series B in September 2024, co-led by Ascenta
  Capital and Woodline Partners with participation from Samsara BioCapital, Enavate Sciences and
  Longitude Capital. OrsoBio publishes a corporate site covering its science, pipeline, team, board,
  publications, events and press releases, but runs no developer program: no API documentation, no
  SDKs, no developer portal, no GitHub organisation and no machine-readable API contract of any
  kind. The only machine-readable surface on orsobio.com is the site's own WordPress CMS route
  index, which the site's robots.txt explicitly disallows at /wp-json/ and which is therefore not
  harvested or catalogued here.
url: https://raw.githubusercontent.com/api-evangelist/orsobio/refs/heads/main/apis.yml
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
specificationVersion: '0.23'
created: '2026-08-04'
modified: '2026-08-04'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Metabolic Disease
- Obesity
- Clinical Trials
- Drug Development
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/orsobio-domain-security.yml
- type: Website
  url: https://orsobio.com/
- type: About
  url: https://orsobio.com/about/
- type: Science
  url: https://orsobio.com/science/
- type: Pipeline
  url: https://orsobio.com/our-pipeline/
- type: Team
  url: https://orsobio.com/team/
- type: News
  url: https://orsobio.com/news/
- type: Blog
  url: https://orsobio.com/news/
- type: BlogRSS
  url: https://orsobio.com/feed/
- type: PrivacyPolicy
  url: https://orsobio.com/privacy-policy/
- type: LinkedIn
  url: https://www.linkedin.com/company/orsobio/
- type: Twitter
  url: https://twitter.com/OrsoBio
- type: Instagram
  url: https://www.instagram.com/orsobio/
- type: SecondaryMarket
  url: https://forgeglobal.com/orsobio_stock/
- type: WellKnown
  url: well-known/orsobio-well-known.yml
- type: LLMsTxt
  url: llms/orsobio-llms.txt
x-enrichment:
  date: '2026-08-04'
  status: minimal
  artifacts_added: 3
  pass: local-v1
x-coverage:
  state: none
  reason: not-a-software-company
  detail: >-
    OrsoBio is a clinical-stage biopharmaceutical company with no developer program — no api.,
    developer., docs., portal. or status. host resolves for orsobio.com, no orsobio GitHub
    organisation exists, and every spec path and /.well-known/ document on the corporate site is
    answered by a SiteGround CAPTCHA interstitial that resolves to the site's WordPress 404 page,
    leaving only the CMS routes at /wp-json/ that the site's own robots.txt disallows.
  evidence:
  - url: https://orsobio.com/openapi.json
    status: 202
  - url: https://orsobio.com/.well-known/agent-card.json
    status: 202
  - url: https://api.github.com/orgs/orsobio
    status: 404
  checked: '2026-08-04'